Foghorn Therapeutics
FHTX
90 hedge funds and large institutions have $148M invested in Foghorn Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
28% more capital inflows, than outflows
Capital inflows: $3.46M | Capital outflows: $2.69M
3% more funds holding
Funds holding: 87 → 90 (+3)
0.28% more ownership
Funds ownership: 72.41% → 72.69% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
+$861K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$538K |
| 3 |
SCS Capital Management
Boston,
Massachusetts
|
+$488K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$387K |
| 5 |
Squarepoint
New York
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$460K |
| 2 |
D.E. Shaw & Co
New York
|
-$390K |
| 3 |
Millennium Management
New York
|
-$328K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$213K |
| 5 |
JP Morgan Chase
New York
|
-$184K |
FHTX Hedge Fund Activity: Q1 2025 in Review
90 of the 7,481 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2025, worth a combined $148M — down 22% from $190M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FHTX positions and 5 closed out — a net gain of 3 holders — while 26 added to existing stakes and 30 trimmed.
The largest buyer was Raymond James Financial, adding an estimated $861K. The largest seller was Fidelity Investments, cutting an estimated $460K.
- 90 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2025, up from 87 in Q4 2024.
- Funds reported $148M of Foghorn Therapeutics stock for Q1 2025, down 22% quarter-over-quarter.
- 8 funds opened new Foghorn Therapeutics positions in Q1 2025 and 5 closed out, a net change of +3 holders.
- The largest Foghorn Therapeutics buyer in Q1 2025 was Raymond James Financial, an estimated $861K added.
- The largest Foghorn Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $460K sold.
Based on aggregated 13F filings for Q1 2025.